The Epstein-Barr virus is one of the most widespread human viruses, with an estimated majority of adults infected worldwide at some point in life. Often acquired in childhood or adolescence, it can remain hidden in the body for years without noticeable symptoms. In some cases, it causes infectious mononucleosis, fatigue, or immune-related complications that last beyond the initial infection.
Recent progress in EBV treatment and research is shifting how scientists view this long-standing virus. From monoclonal antibodies designed to block infection to vaccine trials aiming to prevent disease before it starts, new tools are emerging rapidly. These developments are also opening conversations about virus treatment discovery and how it may help reduce cancer risk and chronic immune complications linked to Epstein-Barr virus.
